Hydroxyurea

"Hydroxyurea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Descriptor ID	D006918
MeSH Number(s)	D02.948.395
Concept/Terms	Hydroxyurea Hydroxyurea Hydroxycarbamid Oncocarbide Oncocarbide Hydrea Hydrea

Below are MeSH descriptors whose meaning is more general than "Hydroxyurea".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Urea [D02.948]
Hydroxyurea [D02.948.395]

Below are MeSH descriptors whose meaning is related to "Hydroxyurea".

Below are MeSH descriptors whose meaning is more specific than "Hydroxyurea".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxyurea" by people in this website by year, and whether "Hydroxyurea" was a major or minor topic of these publications.

Bar chart showing 26 publications over 18 distinct years, with a maximum of 3 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1997	1	0	1
2003	1	0	1
2004	1	1	2
2005	1	0	1
2006	1	1	2
2007	0	1	1
2008	1	0	1
2009	2	1	3
2010	1	0	1
2011	1	1	2
2012	0	1	1
2014	2	0	2
2015	1	1	2
2016	2	0	2
2017	0	1	1
2021	0	1	1
2023	1	0	1

Below are the most recent publications written about "Hydroxyurea" by people in Profiles.

Virgous C, Lyons L, Sakwe A, Nayyar T, Goodwin S, Hildreth J, Osteen K, Bruner-Tran K, Alawode O, Bourne P, Hills ER, Archibong AE. Resumption of Spermatogenesis and Fertility Post Withdrawal of Hydroxyurea Treatment. Int J Mol Sci. 2023 May 27; 24(11).

View in: PubMed
Weaver SB, Rungkitwattanakul D, Singh D. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults With Sickle Cell Disease. J Pharm Pract. 2023 Feb; 36(1):139-148.

View in: PubMed
Han J, Saraf SL, Gordeuk VR. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. Pharmacotherapy. 2020 06; 40(6):535-543.

View in: PubMed
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.

View in: PubMed
Akingbola TS, Tayo BO, Ezekekwu CA, Sonubi O, Zhang X, Saraf SL, Molokie R, Hsu LL, Han J, Cooper RS, Gordeuk VR. "Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia. Am J Hematol. 2019 04; 94(4):E112-E115.

View in: PubMed
Han J, Saraf SL, Molokie RE, Gordeuk VR. Use of metformin in patients with sickle cell disease. Am J Hematol. 2019 01; 94(1):E13-E15.

View in: PubMed
Han J, Saraf SL, Gowhari M, Jain S, Molokie RE, Gordeuk VR. High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. Am J Hematol. 2019 01; 94(1):E5-E7.

View in: PubMed
Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19; 379(3):226-235.

View in: PubMed
Zhou J, Han J, Nutescu EA, Gordeuk VR, Saraf SL, Calip GS. Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. Br J Haematol. 2018 07; 182(2):259-270.

View in: PubMed
Wang Y, Sherchan P, Huang L, Akyol O, McBride DW, Zhang JH. Naja sputatrix Venom Preconditioning Attenuates Neuroinflammation in a Rat Model of Surgical Brain Injury via PLA2/5-LOX/LTB4 Cascade Activation. Sci Rep. 2017 07 14; 7(1):5466.

View in: PubMed

People

Explore

Similar Concepts

Top Journals